VA-DATAXSTREAM
23.4.2024 15:08:30 CEST | Business Wire | Press release
DataXstream LLC, an SAP solution provider focused on order management and point of sale for sales and distribution, today announced it is expanding into the Nordic region after a successful implementation of its OMS+ platform across two key business units for the Martin & Servera group, Sweden’s leading restaurant and catering distributor that specializes in the needs of the restaurant industry.
Learn more about DataXstream OMS+ here.
Martin & Servera is a group of companies based in Stockholm who was faced with the challenge of managing multiple ERP systems that were facing end of life, so they decided to consolidate onto a single instance of SAP S/4 HANA for all their business units. As part of this migration, Martin & Servera turned to DataXstream’s OMS+ cross-channel order management platform to help them enable faster order entry and streamline their sales and order processes between all companies within their organization.
Working with DataXstream’s LATAM delivery team, Kötthallen Sorunda, Sweden's leading wholesaler of meat, game, poultry and charcuterie and Fiskhallen Sorunda, the leading sustainable seafood wholesaler in Sweden, were the first two business units to successfully deploy OMS+ across their live networks. The go-live transition went exceptionally smooth, with over 500 orders created on the first day to meet the demand for the next three days.
“The complex nature of Martin & Servera’s sales and order management environment is exactly what OMS+ is built for. They are processing over 15,000 sales order lines a month and can now streamline and automate those processes in a fraction of the time, resulting in faster order entry and a better customer experience. This go-live stands out as one of the best I have ever been part of, thanks to the excellent integration, support and collaboration between Martin & Servera, the systems integrator, DataXstream and the Steering Committee,” said Diego Perelman, President, DataXstream LATAM. “Our move into the Nordic region highlights the continued need among B2B organizations to reduce complexity and streamline sales order processes within SAP SD environments.”
The OMS+ Difference
The ease of deployment across Martin & Servera’s newly installed S/4 HANA backbone is another hallmark of OMS+ as the only platform on the market today that is directly embedded into SAP as a single interface. This allows Martin & Servera to seamlessly align all their companies’ ERPs and applications onto a single platform, reducing complexity and customization, while giving them access to the same real-time master data from SAP and supporting their unique business needs.
As a result, OMS+ will equip Martin & Servera’s sales associates with:
- Real-time visibility into customer history, discounts, and product availability
- Faster manual order entry capabilities
- Access to real-time material characteristics to swiftly find the right materials for customers
- Full sales communications and tracking
Additionally, as OMS+ is embedded into SAP, it aligns perfectly with their roadmap, ensuring that new SAP functionalities are automatically available in OMS+ and the flexibility of its interface will allow Martin & Servera to adjust it easily to their unique requirements.
“We had several challenges associated with this project including an ongoing S/4 implementation that was going on in parallel to the OMS+ deployment,” said Thomas Tolvanen, IT Manager, Grönsakshallen Sorunda AB. “We are incredibly impressed by DataXstream and their professional delivery team. They have been instrumental in the S/4 process design to streamline our processes and complexity. Likewise, their deep knowledge and expertise to identify bugs and errors in customization and master data has been invaluable to us during this process. DataXstream is one of our most valuable partners.”
For additional information, please visit www.dataxstream.com or find us on the SAP store at https://store.sap.com/dcp/en/product/display-0000006561_live_v1
About Martin & Servera
The Martin & Servera group offers goods, services and knowledge for restaurants and commercial kitchens in Sweden. We are a Swedish, family-owned group. Responsible and long-term business is an important part of our business. The Martin & Servera group consists of Martin & Servera Restauranghandel, Martin & Servera Logistics, Martin & Servera Restaurant Shops, Galatea, the Vegetable Hall Sorunda, the Fish Hall Sorunda and the Meat Hall Sorunda.
About DataXstream
DataXstream is an SAP® Gold and Endorsed App Partner dedicated to building solutions on emerging technologies that maximize the ROI of our customers’ SAP® infrastructure. As members of the SAP® marketplace, DataXstream’s products can be found in the SAP® Store. Your company is already running the most powerful ERP solution; empower your employees with DataXstream’s OMS+ to take your organization’s sale and customer buying experience to new levels.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240423069303/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 08:07:00 CET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 08:00:00 CET | Press release
CE Marking enables marketing and clinical use of the world’s first and only LINAC vault-ready proton therapy system across the European Union Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers a
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom